MedStar Authors catalog › Details for: Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.
Normal view MARC view ISBD view

Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

by Dolman, Sarahfaye F; Kolm, Paul; Weintraub, William S; Zhang, Cheng.
Citation: ; Journal of the American College of Cardiology. 74(19):2333-2345, 2019 11 12..Journal: Journal of the American College of Cardiology.Published: ; 2019; ISSN: 0735-1097.Full author list: Appelbaum E; Desai MY; Desvigne-Nickens P; DiMarco JP; Dolman SF; Friedrich MG; Geller N; Harper AR; HCMR Investigators; Ho CY; Jarolim P; Jerosch-Herold M; Kim DY; Kolm P; Kramer CM; Kwong RY; Maron MS; Neubauer S; Piechnik SK; Schulz-Menger J; Thomson K; Watkins H; Weintraub WS; Zhang C.UI/PMID: 31699273.Subject(s): Adult | United States | Registries | National Heart, Lung, and Blood Institute (U.S.) | Middle Aged | Male | Magnetic Resonance Imaging | Humans | Female | Echocardiography | Cardiomyopathy, Hypertrophic/me [Metabolism] | *Cardiomyopathy, Hypertrophic/ep [Epidemiology] | *Cardiomyopathy, Hypertrophic/di [Diagnosis] | Biomarkers/me [Metabolism] | AgedInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: ; J Am Coll Cardiol. 74(19):2333-2345, 2019 11 12.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007.Abstract: BACKGROUND: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective registry of 2,755 patients with hypertrophic cardiomyopathy (HCM) recruited from 44 sites in 6 countries.Abstract: CONCLUSIONS: The HCMR population has characteristics of low-risk HCM. Ninety-three percent had no or only mild functional limitation. Baseline data separated patients broadly into 2 categories. One group was sarcomere mutation positive and more likely had reverse septal curvature morphology, more fibrosis, but less resting obstruction, whereas the other was sarcomere mutation negative and more likely had isolated basal septal hypertrophy with obstruction, but less fibrosis. Further follow-up will allow better understanding of these subgroups and development of an improved risk prediction model incorporating all these markers. Copyright (c) 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.Abstract: METHODS: Demographic and echocardiographic data were collected. Patients underwent CMR including cine imaging, late gadolinium enhancement imaging (LGE) (replacement fibrosis), and T1 mapping for measurement of extracellular volume as a measure of interstitial fibrosis. Blood was drawn for the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT), and genetic analysis.Abstract: OBJECTIVES: The authors sought to improve risk prediction in HCM by incorporating cardiac magnetic resonance (CMR), genetic, and biomarker data.Abstract: RESULTS: A total of 2,755 patients were studied. Mean age was 49 +/- 11 years, 71% were male, and 17% non-white. Mean ESC (European Society of Cardiology) risk score was 2.48 +/- 0.56. Eighteen percent had a resting left ventricular outflow tract (LVOT) gradient >=30 mm Hg. Thirty-six percent had a sarcomere mutation identified, and 50% had any LGE. Sarcomere mutation-positive patients were more likely to have reverse septal curvature morphology, LGE, and no significant resting LVOT obstruction. Those that were sarcomere mutation negative were more likely to have isolated basal septal hypertrophy, less LGE, and more LVOT obstruction. Interstitial fibrosis was present in segments both with and without LGE. Serum NT-proBNP and cTnT levels correlated with increasing LGE and extracellular volume in a graded fashion.

Powered by Koha